In one study on the clinical outcome of pembrolizumab versus chemotherapy in lung cancer patients, it was observed that the treatment outcomes appeared to be comparable irrespective of the presence of STK11, KEAP1, or KRAS mutations [113]. Here, KEAP1 is linked to lung cancer.